Apnimed eyes sleep apnea drug submission after positive phase 3 results
Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. The Massachusetts biotech reported May 19 that AD109 met the primary endpoint of a phase 3 trial, reducing sleep apnea severity by a statistically significant 55.6% compared to baseline.
Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. The Massachusetts biotech reported May 19 that AD109 met the primary endpoint of a phase 3 trial, reducing sleep apnea severity by a statistically significant 55.6% compared to baseline.
